Fig. 4

A and B Expression of key proteins in the PI3K-AKT signaling pathway after silencing of UBE2T and addition of MHY1485. (*P < 0.05 versus si-NC; #P < 0.05 versus si-UBE2T). Data are presented as mean ± standard deviation and analyzed via repeated-measures analysis of variance (ANOVA). The experiment was repeated thrice, independently. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MTOR, mechanistic target of rapamycin; PI3K-AKT, phosphatidylinositol 3 kinase/protein kinase B; p-PI3K, phosphorylated-PI3K; si-NC, small interfering RNA-negative control; UBE2T, ubiquitin-binding enzyme E2T. C and D Changes in the invasive ability of SKOV3 cells after silencing of UBE2T and addition of MHY1485. si-NC, small interfering RNA-negative control; UBE2T, ubiquitin-binding enzyme E2T. E–G Expression of key proteins in EMT after silencing of UBE2T in SKOV3 and HO8910 cells. *P < 0.05. Data are presented as mean ± standard deviation and analyzed via repeated-measures analysis of variance (ANOVA). The experiment was repeated thrice, independently. EMT, epithelial–mesenchymal transition; E-cad, E-cadherin; N-cad, neurocadherin; si-NC, small interfering RNA-negative control; UBE2T, ubiquitin-binding enzyme E2T